BPMC Blueprint Medicines Corp

Price (delayed)

$104.21

Market cap

$6.1B

P/E Ratio

16.62

Dividend/share

N/A

EPS

$6.27

Enterprise value

$5.65B

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company ...

Highlights
The net income has soared by 186% YoY and by 4.6% QoQ
Blueprint Medicines's EPS has surged by 182% YoY and by 7% QoQ
Blueprint Medicines's equity has surged by 129% YoY but it has decreased by 5% QoQ
BPMC's quick ratio is down by 33% since the previous quarter but it is up by 2.3% year-on-year

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
58.57M
Market cap
$6.1B
Enterprise value
$5.65B
Valuations
Price to earnings (P/E)
16.62
Price to book (P/B)
4.58
Price to sales (P/S)
7.35
EV/EBIT
16.72
EV/EBITDA
16.12
EV/Sales
6.82
Earnings
Revenue
$828.1M
EBIT
$337.92M
EBITDA
$350.48M
Free cash flow
$407.06M
Per share
EPS
$6.27
Free cash flow per share
$6.97
Book value per share
$22.78
Revenue per share
$14.18
TBVPS
$26.86
Balance sheet
Total assets
$1.57B
Total liabilities
$239.99M
Debt
$85.74M
Equity
$1.33B
Working capital
$578.67M
Liquidity
Debt to equity
0.06
Current ratio
5.61
Quick ratio
5.37
Net debt/EBITDA
-1.29
Margins
EBITDA margin
42.3%
Gross margin
99.2%
Net margin
41.1%
Operating margin
40.9%
Efficiency
Return on assets
21%
Return on equity
24.7%
Return on invested capital
35.2%
Return on capital employed
23.4%
Return on sales
40.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
0.52%
1 week
1.96%
1 month
-2.02%
1 year
-0.84%
YTD
-7.08%
QTD
1.36%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$828.1M
Gross profit
$821.23M
Operating income
$338.65M
Net income
$340.15M
Gross margin
99.2%
Net margin
41.1%
The net income has soared by 186% YoY and by 4.6% QoQ
The operating income has soared by 183% YoY and by 5% from the previous quarter
BPMC's net margin has soared by 108% year-on-year and by 2.2% since the previous quarter
The operating margin has soared by 108% YoY and by 2.8% from the previous quarter

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
16.62
P/B
4.58
P/S
7.35
EV/EBIT
16.72
EV/EBITDA
16.12
EV/Sales
6.82
Blueprint Medicines's EPS has surged by 182% YoY and by 7% QoQ
Blueprint Medicines's equity has surged by 129% YoY but it has decreased by 5% QoQ
The price to book (P/B) is 24% lower than the 5-year quarterly average of 6.0 but 15% higher than the last 4 quarters average of 4.0
The P/S is 93% below the 5-year quarterly average of 98.8 but 8% above the last 4 quarters average of 6.8
Blueprint Medicines's revenue has increased by 2.3% QoQ

Efficiency

How efficient is Blueprint Medicines business performance
The ROIC has soared by 149% YoY but it has decreased by 8% from the previous quarter
The company's return on assets has surged by 142% YoY but it fell by 7% QoQ
BPMC's return on equity has surged by 135% year-on-year but it is down by 10% since the previous quarter
Blueprint Medicines's return on sales has surged by 108% YoY and by 2.5% QoQ

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's total assets has surged by 92% year-on-year but it is down by 3.5% since the previous quarter
Blueprint Medicines's current ratio has decreased by 33% from the previous quarter but it has increased by 3.7% YoY
BPMC's debt is 94% smaller than its equity
Blueprint Medicines's equity has surged by 129% YoY but it has decreased by 5% QoQ
BPMC's debt to equity has dropped by 63% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.